First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and pancreatic adenocarcinomas, according to Phanes Therapeutics, Inc. (Phanes), an…